Intravenous immunoglobulin in neurology-mode of action and clinical efficacy

Nature Reviews Neurology

Volumn 11, Issue 2, 2015, Pages 80-89

  Lünemann, Jan D ^a   Nimmerjahn, Falk ^b   Dalakas, Marinos C ^c  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; FAS ANTIGEN; FAS LIGAND; FC RECEPTOR; FC RECEPTOR IIB; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; TUMOR NECROSIS FACTOR; BIOLOGICAL MARKER;

ACUTE KIDNEY TUBULE NECROSIS; ALZHEIMER DISEASE; ANAPHYLAXIS; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE ENCEPHALITIS; BACKACHE; BRAIN VASOSPASM; CHILL; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; COMPLEX REGIONAL PAIN SYNDROME TYPE I; CONTROLLED CLINICAL TRIAL (TOPIC); DERMATOMYOSITIS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENCEPHALITIS; FATIGUE; FEVER; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; HYPERTENSION; HYPONATREMIA; IMMUNOMODULATION; IMMUNOTHERAPY; LEUKOPENIA; MOTOR NEUROPATHY; MULTIPLE SCLEROSIS; MYALGIA; MYASTHENIA GRAVIS; MYELOOPTIC NEUROPATHY; MYOSITIS; NARCOLEPSY; NAUSEA; NECROTIZING AUTOIMMUNE MYOSITIS; NEUROLOGIC DISEASE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMAPHERESIS; POLYMYOSITIS; POSTPOLIOMYELITIS SYNDROME; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN MANIFESTATION; STIFF MAN SYNDROME; THORAX PAIN; THROMBOEMBOLISM; UPREGULATION; ANIMAL; CLINICAL TRIAL (TOPIC); DISEASE MODEL; METABOLISM; MOUSE; NERVOUS SYSTEM DISEASES; NEUROLOGY; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MICE; NERVOUS SYSTEM DISEASES; NEUROLOGY; TREATMENT OUTCOME;

EID: 84926160722     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2014.253     Document Type: Review

References (107)

1. Casadevall, A., Dadachova, E. & Pirofski, L. A. Passive antibody therapy for infectious diseases. Nat. Rev. Microbiol. 2, 695-703 (2004).
2. Viard, I. et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282, 490-493 (1998).
3. Le Pottier, L. et al. Intravenous immunoglobulin and cytokines: focus on tumor necrosis factor family members BAFF and APRIL. Ann. N. Y. Acad. Sci. 1110, 426-432 (2007).
4. Prins, C., Gelfand, E. W. & French, L. E. Intravenous immunoglobulin: properties, mode of action and practical use in dermatology. Acta Derm. Venereol. 87, 206-218 (2007).
5. Rossi, F. & Kazatchkine, M. D. Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J. Immunol. 143, 4104-4109 (1989).
6. Schwab, I. & Nimmerjahn, F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat. Rev. Immunol. 13, 176-189 (2013).
7. Vassilev, T. et al. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin. Exp. Immunol. 92, 369-372 (1993).
8. Vassilev, T. L. et al. Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). Blood 93, 3624-3631 (1999).
9. von Gunten, S. et al. Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations. Blood 108, 4255-4259 (2006).
10. von Gunten, S. & Simon, H. U. Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: implications for the clinical use of intravenous immunoglobulins (IVIg). Autoimmun. Rev. 7, 453-456 (2008).
11. von Gunten, S. et al. Intravenous immunoglobulin contains a broad repertoire of anti-carbohydrate antibodies that is not restricted to the IgG2 subclass. J. Allergy Clin. Immunol. 123, 1268-1276.e15 (2009).
12. von Gunten, S. et al. Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies. J. Allergy Clin. Immunol. 119, 1005-1011 (2007).
13. Basta, M., Langlois, P. F., Marques, M., Frank, M. M. & Fries, L. F. High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance. Blood 74, 326-333 (1989).
14. Debre, M. et al. Infusion of Fc? fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 342, 945-949 (1993).
15. Anthony, R. M. et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320, 373-376 (2008).
16. Bruhns, P., Samuelsson, A., Pollard, J. W. & Ravetch, J. V. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 18, 573-581 (2003).
17. Kaneko, Y., Nimmerjahn, F., Madaio, M. P. & Ravetch, J. V. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J. Exp. Med. 203, 789-797 (2006).
18. Kaneko, Y., Nimmerjahn, F. & Ravetch, J. V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313, 670-673 (2006).
19. Samuelsson, A., Towers, T. L. & Ravetch, J. V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291, 484-486 (2001).
20. Hansen, R. J. & Balthasar, J. P. Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thromb. Haemost. 88, 898-899 (2002).
21. Li, N. et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J. Clin. Invest. 115, 3440-3450 (2005).
22. Tackenberg, B. et al. Impaired inhibitory Fc? receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc. Natl Acad. Sci. USA 106, 4788-4792 (2009).
23. Mackay, M. et al. Selective dysregulation of the Fc?IIB receptor on memory B cells in SLE. J. Exp. Med. 203, 2157-2164 (2006).
24. Anthony, R. M., Kobayashi, T., Wermeling, F. & Ravetch, J. V. Intravenous gammaglobulin suppresses inflammation through a novel TH2 pathway. Nature 475, 110-113 (2011).
25. Kaneko, Y., Nimmerjahn, F., Madaio, M. P. & Ravetch, J. V. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J. Exp. Med. 203, 789-797 (2006).
26. Arnold, J. N., Wormald, M. R., Sim, R. B., Rudd, P. M. & Dwek, R. A. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 25, 21-50 (2007).
27. Schwab, I., Biburger, M., Kronke, G., Schett, G. & Nimmerjahn, F. IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1. Eur. J. Immunol. 42, 826-830 (2012).
28. Campbell, I. K. et al. Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils. J. Immunol. 192, 5031-5038 (2014).
29. Othy, S. et al. Sialylation may be dispensable for reciprocal modulation of helper T cells by intravenous immunoglobulin. Eur. J. Immunol. 44, 2059-2063 (2014).
30. Dalakas, M. C. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve 22, 1479-1497 (1999).
31. Dalakas, M. C. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat. Rev. Neurol. 7, 507-517 (2011).
32. van der Meche, F. G. & Schmitz, P. I. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N. Engl. J. Med. 326, 1123-1129 (1992).
33. [No authors listed]. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Lancet 349, 225-230 (1997).
34. Hughes, R. A. et al. Clinical applications of intravenous immunoglobulins in neurology. Clin. Exp. Immunol. 158 (Suppl. 1), 34-42 (2009).
35. Kuitwaard, K. et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann. Neurol. 66, 597-603 (2009).
36. Dyck, P. J. et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann. Neurol. 36, 838-845 (1994).
37. Hughes, R. et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann. Neurol. 50, 195-201 (2001).
38. Mendell, J. R. et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 56, 445-449 (2001).
39. Hughes, R. A. et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 7, 136-144 (2008).
40. Merkies, I. S. et al. Health-related quality-of-life improvements in CIDP with immune globulin IV 10%: the ICE Study. Neurology 72, 1337-1344 (2009).
41. Bril, V. et al. Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIV. Muscle Nerve 39, 448-455 (2009).
42. Latov, N. et al. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch. Neurol. 67, 802-807 (2010).
43. Vermeulen, M. et al. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J. Neurol. Neurosurg. Psychiatry 56, 36-39 (1993).
44. Hahn, A. F., Bolton, C. F., Zochodne, D. & Feasby, T. E. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, cross-over study. Brain 119, 1067-1077 (1996).
45. Iijima, M. et al. Single nucleotide polymorphism of TAG-1 influences IVIg responsiveness of Japanese patients with CIDP. Neurology 73, 1348-1352 (2009).
46. Klehmet, J. et al. Effective treatment with intravenous immunoglobulins reduces autoreactive T-cell response in patients with CIDP. J. Neurol. Neurosurg. Psychiatry http://dx.doi.org/10.1136/jnnp-2014-307708.
47. Dalakas, M. C. Pathogenesis of immune-mediated neuropathies. Biochim. Biophys. Acta http://dx.doi.org/10.1016/j.bbadis.2014.06.013.
48. Hahn, A. F. et al. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy. J. Peripher. Nerv. Syst. 18, 321-330 (2013).
49. Federico, P., Zochodne, D. W., Hahn, A. F., Brown, W. F. & Feasby, T. E. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 55, 1256-1262 (2000).
50. Dalakas, M. C. et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann. Neurol. 40, 792-795 (1996).
51. Comi, G. et al. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J. Neurol. 249, 1370-1377 (2002).
52. Vaccaro, C., Zhou, J., Ober, R. J. & Ward, E. S. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat. Biotechnol. 23, 1283-1288 (2005).
53. Barbosa, D. et al. Polyomavirus BK viremia in kidney transplant recipients after desensitization with IVIg and rituximab. Transplantation 97, 755-761 (2013).
54. Jordan, S. C., Vo, A., Lai, C. H. & Reinsmoen, N. Defining the benefits of desensitization therapy. Transplantation 95, e31-e32 (2013).
55. Hung, I. F. et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A (H1N1) infection. Chest 144, 464-473 (2013).
56. Gajdos, P., Chevret, S., Clair, B., Tranchant, C. & Chastang, C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann. Neurol. 41, 789-796 (1997).
57. Gajdos, P. et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. Arch. Neurol. 62, 1689-1693 (2005).
58. Zinman, L., Ng, E. & Bril, V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 68, 837-841 (2007).
59. Gajdos, P., Chevret, S. & Toyka, K. V. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database of Systematic Reviews, Issue 12. Art. No.: CD002277. http://dx.doi.org/10.1002/14651858.CD002277.pub4.
60. Dalakas, M. C. IVIg in the chronic management of myasthenia gravis: is it enough for your money? J. Neurol. Sci. 338, 1-2 (2014).
61. Dalakas, M. C. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 291, 2367-2375 (2004).
62. Bain, P. G. et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 47, 678-683 (1996).
63. Dalakas, M. C. et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N. Engl. J. Med. 329, 1993-2000 (1993).
64. Basta, M. & Dalakas, M. C. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J. Clin. Invest. 94, 1729-1735 (1994).
65. Raju, R. & Dalakas, M. C. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 128, 1887-1896 (2005).
66. Chalela, J. A. Guillain-Barre variant in the deployed setting. Mil. Med. 178, e1156-e1158 (2013).
67. Nagelkerke, S. Q. et al. Inhibition of Fc?R-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and Fc?RIIb in human macrophages. Blood 124, 3709-3718 (2014).
68. Dalakas, M. C. et al. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 48, 712-716 (1997).
69. Dalakas, M. C. Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis. Neurology 51, S37-S45 (1998).
70. Walter, M. C. et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J. Neurol. 247, 22-28 (2000).
71. Dalakas, M. C. et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 56, 323-327 (2001).
72. Dalakas, M. C. et al. High-dose intravenous immune globulin for stiff-person syndrome. N. Engl. J. Med. 345, 1870-1876 (2001).
73. Sorensen, P. S., Haas, J., Sellebjerg, F., Olsson, T. & Ravnborg, M. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology 63, 2028-2033 (2004).
74. Visser, L. H. et al. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS. Mult. Scler. 10, 89-91 (2004).
75. Fazekas, F. et al. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology 71, 265-271 (2008).
76. Hommes, O. R. et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 364, 1149-1156 (2004).
77. Achiron, A. et al. Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J. Neurol. 251, 1133-1137 (2004).
78. Dodel, R. C. et al. Intravenous immunoglobulins containing antibodies against ?-amyloid for the treatment of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 75, 1472-1474 (2004).
79. DeMattos, R. B. et al. Peripheral anti-A? antibody alters CNS and plasma A? clearance and decreases brain A? burden in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 98, 8850-8855 (2001).
80. Leoyklang, P. et al. Sialylation of Thomsen-Friedenreich antigen is a noninvasive blood-based biomarker for GNE myopathy. Biomark. Med. 8, 641-652 (2014).
81. Ahmed, A. A. et al. Structural characterization of anti-inflammatory immunoglobulin G Fc proteins. J. Mol. Biol. 426, 3166-3179 (2014).
82. Gonzalez, H. et al. Intravenous immunoglobulin for post-polio syndrome: a randomised controlled trial. Lancet Neurol. 5, 493-500 (2006).
83. Juji, T., Satake, M., Honda, Y. & Doi, Y. HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive. Tissue Antigens 24, 316-319 (1984).
84. Mignot, E. & Thorsby, E. Narcolepsy and the HLA system. N. Engl. J. Med. 344, 692 (2001).
85. Plazzi, G. et al. Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy. J. Neurol. 255, 1549-1554 (2008).
86. von Gunten, S. et al. IVIG pluripotency and the concept of Fc-sialylation: challenges to the scientist. Nat. Rev. Immunol. 14, 349 (2014).
87. Goebel, A. et al. Intravenous immunoglobulin treatment of the complex regional pain syndrome: a randomized trial. Ann. Intern. Med. 152, 152-158 (2010).
88. Elsone, L. et al. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult. Scler. 20, 501-504 (2014).
89. Fokkink, W. J. et al. IgG Fc N-glycosylation in Guillain-Barré syndrome treated with immunoglobulins. J. Proteome Res. 13, 1722-1730 (2014).
90. Donofrio, P. D. et al. Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee. Muscle Nerve 40, 890-900 (2009).
91. Woodruff, R. K., Grigg, A. P., Firkin, F. C. & Smith, I. L. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet 2, 217-218 (1986).
92. Dalakas, M. C. & Clark, W. M. Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record. Neurology 60, 1736-1737 (2003).
93. Dalakas, M. C. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 44, 223-226 (1994).
94. Voltz, R., Rosen, F. V., Yousry, T., Beck, J. & Hohlfeld, R. Reversible encephalopathy with cerebral vasospasm in a Guillain-Barré syndrome patient treated with intravenous immunoglobulin. Neurology 46, 250-251 (1996).
95. Germishuizen, W. A., Gyure, D. C., Stubbings, D. & Burnouf, T. Quantifying the thrombogenic potential of human plasma-derived immunoglobulin products. Biologicals 42, 260-270 (2014).
96. Dalakas, M. C. Intravenous immune globulin therapy for neurologic diseases. Ann. Intern. Med. 126, 721-730 (1997).
97. Dalakas, M. C. Update on the use of intravenous immune globulin in the treatment of patients with inflammatory muscle disease. J. Clin. Immunol. 15 (Suppl. 6), 70S-75S (1995).
98. Sekul, E. A., Cupler, E. J. & Dalakas, M. C. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann. Intern. Med. 121, 259-262 (1994).
99. Bjorkander, J. et al. Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies. J. Clin. Immunol. 7, 8-15 (1987).
100. Horn, J. et al. Anti-IgA antibodies in common variable immunodeficiency (CVID): diagnostic workup and therapeutic strategy. Clin. Immunol. 122, 156-162 (2007).
101. Burks, A. W., Sampson, H. A. & Buckley, R. H. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. N. Engl. J. Med. 314, 560-564 (1986).
102. Ahsan, N. Intravenous immunoglobulin induced-nephropathy: a complication of IVIG therapy. J. Nephrol. 11, 157-161 (1998).
103. Ahsan, N., Palmer, B. F., Wheeler, D., Greenlee, R. G. Jr & Toto, R. D. Intravenous immunoglobulin-induced osmotic nephrosis. Arch. Intern. Med. 154, 1985-1987 (1994).
104. Gelfand, E. W. Intravenous immune globulin in autoimmune and inflammatory diseases. N. Engl. J. Med. 368, 777 (2013).
105. McCrone, P. et al. Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. Eur. J. Neurol. 10, 687-694 (2003).
106. Koffman, B. M. & Dalakas, M. C. Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: assessments based on controlled treatment trials in patients with neurological diseases. Muscle Nerve 20, 1102-1107 (1997).
107. Markvardsen, L. H. et al. Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy. Eur. J. Neurol. 21, 1465-1470 (2014).